CMS Officials Stress Coverage Decision Timeline At ACLA Panel
Executive Summary
Device developers who want to ensure the best possible reimbursement for their products should be thoughtful in how they approach the US Centers for Medicare and Medicaid Services, agency officials said during a recent meeting.
You may also be interested in...
So The Public Health Emergency Is Over. Now What?
In January, US President Joe Biden announced that the COVID-19 public health emergency will expire in May. Dr. David Feldman, chief medical officer at The Doctors Company, spoke to Medtech Insight about what the official end of the emergency means for average Americans.
News We’re Watching – FDA Mammography Update, SVB Collapse, Zoll's Data Breach, And More
News we are keeping an eye on this week includes the FDA’s first traditional market authorization for a COVID-19 test and its approval of a new neurological diagnostic. The agency also updated its device shortage list and revised mammography guidelines.
Pain Device Firm’s Undoing Over $16K ‘Piece of Plastic’
Neuromodulation company Stimwave has agreed to pay $10M in fines and the ex-CEO is facing health care fraud charges after a whistleblower revealed the company was selling a fraudulent “receiver” component.